IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.